Dopamine Transporter Imaging Assessment of Parkinson's Disease Progression
Abstract
The primary goal of this study is to investigate whether sequential dopamine transporter imaging using 123Ib-CIT and SPECT, a marker of dopamine terminal integrity, will provide a quantitative biomarker of Parkinson's disease progression in subjects with early Parkison's disease during a nine month imaging interval. The subjects in this study are a subset of an NIH funded clinical trial call ELLOPA, designed to examine the effect of L-dopa on the r te of progression of Parkinson's disease. All subjects have been and will be recruited and clinically evaluated through their participation in that study. During the first grant ye r, 94 subjects recruited from 27 ELLOPA study sites have undergone their baseline 1231B-C T SPECT scan. This study will directly evaluate in vivo the rate of ongoing dopaminergic ne ronal degeneration in early Parkinson's disease, whether the rate of ongoing dopaminergic neuro al degeneration is affected by L-dopa, a potential neurotoxin, and whether the changes in imaging uptake correlate with clinical measures of disease progression. Finally, we will use 123 B-CIT and SPECT imaging to investigate the role of the dopamine transporter in the develo ment of neurotoxicity from L-dopa and related compounds.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2000
- Accession Number
- ADA383333
Entities
People
- Kenneth Marek
Organizations
- Yale University